endocrinology
Bone health

Denosumab prescriptions up, testosterone down: DUSC

Half of all people starting osteoporosis therapy last year were prescribed denosumab (Prolia) and a large number of people already on treatment switched to the monoclonal antibody, according to the PBAC Drug Utilisation Sub-Committee Outcome Statement. The higher than expected uptake of denosumab may relate to patient and clinician preference for a medicine given as ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic